Table content
# Sarepta Therapeutics Shares Drop Sharply After Individual’s Demise
### Individual was being treated for muscular degeneration
*Released March 18, 2025*
*10:29 AM Eastern Time*
### Main Aspects
* Sarepta Therapeutics revealed that an individual being treated for Duchenne muscular degeneration passed away due to severe hepatic insufficiency.
* The drugmaker mentioned that severe hepatic harm is an acknowledged possible adverse reaction of Elevidys.
* Sarepta’s share value decreased by 23% after the report.
Sarepta Therapeutics (SRPT) communicated that an individual with Duchenne muscular degeneration who was getting Elevidys therapy passed away due to severe hepatic insufficiency (ALF). The share value plunged 23% after the declaration.
The drugmaker indicated that while this is the initial documented demise after giving the medication, severe hepatic harm is an acknowledged possible adverse reaction of Elevidys and other related gene therapies.
Sarepta clarified that the individual lately had a cytomegalovirus (CMV) illness, which attending doctors think might have been a contributing element.
The firm mentioned that it will proceed to gather and assess details regarding the occurrence and has informed health regulators. Sarepta also intends to revise its prescribing data to completely represent this occurrence.
*Investopedia* has reached out to the firm to ask if it might contemplate taking any extra actions in reaction to this occurrence.
Including today’s steep decline, Sarepta Therapeutics’ share value has forfeited over 35% of its worth over the previous year.
Modification guidelines. Observe NVIDIA Chief Executive Officer Jensen Huang’s Online Broadcast Today
